Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 742

1.

Blockade of the interaction of leukotriene b4 with its receptor prevents development of autoimmune uveitis.

Liao T, Ke Y, Shao WH, Haribabu B, Kaplan HJ, Sun D, Shao H.

Invest Ophthalmol Vis Sci. 2006 Apr;47(4):1543-9.

PMID:
16565390
2.

Severe chronic experimental autoimmune uveitis (EAU) of the C57BL/6 mouse induced by adoptive transfer of IRBP1-20-specific T cells.

Shao H, Liao T, Ke Y, Shi H, Kaplan HJ, Sun D.

Exp Eye Res. 2006 Feb;82(2):323-31. Epub 2005 Aug 25.

PMID:
16125173
3.

CCR5-deficient mice develop experimental autoimmune uveoretinitis in the context of a deviant effector response.

Takeuchi A, Usui Y, Takeuchi M, Hattori T, Kezuka T, Suzuki J, Okunuki Y, Iwasaki T, Haino M, Matsushima K, Usui M.

Invest Ophthalmol Vis Sci. 2005 Oct;46(10):3753-60.

PMID:
16186359
4.

Anti-CD137 mAb treatment inhibits experimental autoimmune uveitis by limiting expansion and increasing apoptotic death of uveitogenic T cells.

Shao H, Fu Y, Liao T, Peng Y, Chen L, Kaplan HJ, Sun D.

Invest Ophthalmol Vis Sci. 2005 Feb;46(2):596-603.

PMID:
15671287
5.

Protective effect of the type IV phosphodiesterase inhibitor rolipram in EAU: protection is independent of IL-10-inducing activity.

Xu H, Strassmann G, Chan CC, Rizzo LV, Silver PB, Wiggert B, Caspi RR.

Invest Ophthalmol Vis Sci. 1999 Apr;40(5):942-50.

PMID:
10102291
6.
7.

Endogenous IL-12 is required for induction and expression of experimental autoimmune uveitis.

Tarrant TK, Silver PB, Chan CC, Wiggert B, Caspi RR.

J Immunol. 1998 Jul 1;161(1):122-7.

8.

Use of ACAID to suppress interphotoreceptor retinoid binding protein-induced experimental autoimmune uveitis.

Hara Y, Caspi RR, Wiggert B, Chan CC, Streilein JW.

Curr Eye Res. 1992;11 Suppl:97-100.

PMID:
1424755
9.

Peptide-mediated suppression of experimental autoimmune uveoretinitis in mice: development of a peptide vaccine.

Kezuka T, Sakai J, Yokoi H, Takeuchi M, Okada A, Taguchi O, Usui M, Mizuguchi J.

Int Immunol. 1996 Aug;8(8):1229-35.

PMID:
8918692
10.

Interphotoreceptor retinoid-binding protein (IRBP)-deficient C57BL/6 mice have enhanced immunological and immunopathogenic responses to IRBP and an altered recognition of IRBP epitopes.

Avichezer D, Liou GI, Chan CC, Lewis GM, Wiggert B, Donoso LA, Nickerson JM, Crawford MA, Caspi RR.

J Autoimmun. 2003 Nov;21(3):185-94.

PMID:
14599843
11.

Identification of a new epitope of human IRBP that induces autoimmune uveoretinitis in mice of the H-2b haplotype.

Avichezer D, Silver PB, Chan CC, Wiggert B, Caspi RR.

Invest Ophthalmol Vis Sci. 2000 Jan;41(1):127-31.

PMID:
10634611
12.

IL-18 not required for IRBP peptide-induced EAU: studies in gene-deficient mice.

Jiang HR, Wei X, Niedbala W, Lumsden L, Liew FY, Forrester JV.

Invest Ophthalmol Vis Sci. 2001 Jan;42(1):177-82.

PMID:
11133864
13.

Administration of a peptide inhibitor of alpha4-integrin inhibits the development of experimental autoimmune uveitis.

Martín AP, de Moraes LV, Tadokoro CE, Commodaro AG, Urrets-Zavalia E, Rabinovich GA, Urrets-Zavalia J, Rizzo LV, Serra HM.

Invest Ophthalmol Vis Sci. 2005 Jun;46(6):2056-63.

PMID:
15914623
14.

Contribution of CD4+CD25+ T cells to the regression phase of experimental autoimmune uveoretinitis.

Sun M, Yang P, Du L, Zhou H, Ren X, Kijlstra A.

Invest Ophthalmol Vis Sci. 2010 Jan;51(1):383-9. doi: 10.1167/iovs.09-3514. Epub 2009 Aug 20.

PMID:
19696173
15.

Blockade of interleukin-6 signaling suppresses experimental autoimmune uveoretinitis by the inhibition of inflammatory Th17 responses.

Hohki S, Ohguro N, Haruta H, Nakai K, Terabe F, Serada S, Fujimoto M, Nomura S, Kawahata H, Kishimoto T, Naka T.

Exp Eye Res. 2010 Aug;91(2):162-70. doi: 10.1016/j.exer.2010.04.009. Epub 2010 Apr 24.

PMID:
20420831
16.

Osteopontin is proinflammatory in experimental autoimmune uveitis.

Hikita ST, Vistica BP, Jones HR, Keswani JR, Watson MM, Ericson VR, Ayoub GS, Gery I, Clegg DO.

Invest Ophthalmol Vis Sci. 2006 Oct;47(10):4435-43.

PMID:
17003437
17.

Suppression of spontaneous uveoretinitis development by non-immunopathogenic peptide immunization.

Takeuchi M, Kezuka T, Inoue H, Sakai J, Usui M, Takahashi T, Taguchi O.

Eur J Immunol. 1998 May;28(5):1578-86.

18.

Blockade of interleukin-6 signaling suppresses not only th17 but also interphotoreceptor retinoid binding protein-specific Th1 by promoting regulatory T cells in experimental autoimmune uveoretinitis.

Haruta H, Ohguro N, Fujimoto M, Hohki S, Terabe F, Serada S, Nomura S, Nishida K, Kishimoto T, Naka T.

Invest Ophthalmol Vis Sci. 2011 May 17;52(6):3264-71. doi: 10.1167/iovs.10-6272.

PMID:
21330657
19.

Antigen-specific inhibition of experimental autoimmune uveoretinitis by bone marrow-derived immature dendritic cells.

Jiang HR, Muckersie E, Robertson M, Forrester JV.

Invest Ophthalmol Vis Sci. 2003 Apr;44(4):1598-607.

PMID:
12657598
20.

Staphylococcal enterotoxin B is involved in aggravation and recurrence of murine experimental autoimmune uveoretinitis via Vbeta8+CD4+ T cells.

Kohno H, Sakai T, Tsuneoka H, Imanishi K, Saito S.

Exp Eye Res. 2009 Oct;89(4):486-93. doi: 10.1016/j.exer.2009.05.009. Epub 2009 Jun 11.

PMID:
19523946

Supplemental Content

Support Center